Abstract
This systematic review aims to summarize epigenome-wide studies on aberrant DNA methylation and its association with survival in patients with gastrointestinal adenocarcinoma. The 15 studies identified showed a large variety of methodological approaches for the identification of prognostic epigenetic markers from genome-wide methylation analyses. None of the findings were reported by more than one study in this systematic review. Further validation studies, a better reporting of methods and results are needed, as well as a clearer definition of investigated outcomes. At present, no conclusions can be drawn on the clinical relevance of the reported epigenetic markers.
Author supplied keywords
Cite
CITATION STYLE
d’Errico, M., Alwers, E., Zhang, Y., Edelmann, D., Brenner, H., & Hoffmeister, M. (2020, January 1). Identification of prognostic DNA methylation biomarkers in patients with gastrointestinal adenocarcinomas: A systematic review of epigenome-wide studies. Cancer Treatment Reviews. W.B. Saunders Ltd. https://doi.org/10.1016/j.ctrv.2019.101933
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.